Get the Stockscreener App
7.62
1.46%
0.11
Mbx Biosciences Inc stock is traded at $7.62, with a volume of 218.71K.
It is up +1.46% in the last 24 hours and down -13.90% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
See More
Previous Close:
$7.51
Open:
$7.48
24h Volume:
218.71K
Relative Volume:
0.76
Market Cap:
$248.34M
Revenue:
-
Net Income/Loss:
$-47.20M
P/E Ratio:
-4.8681
EPS:
-1.5653
Net Cash Flow:
$-43.65M
1W Performance:
+21.53%
1M Performance:
-13.90%
6M Performance:
-67.10%
1Y Performance:
+0.00%
1-Day Range:
$7.09
$7.85
1-Week Range:
$6.34
$7.86
52-Week Range:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
7.62 | 248.34M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
Mbx Biosciences Inc Stock (MBX) Latest News
5,593 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Corebridge Financial Inc. - Defense World
25,000 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Norges Bank - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Receives $37.40 Consensus Price Target from Brokerages - Defense World
MBX Biosciences initiated at Market Outperform by Citizens - MSN
Director Makes Bold Move with Major MBX Biosciences Stock Purchase - TipRanks
JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation - Nasdaq
MBX Biosciences: Innovative PEP Platform and Promising Pipeline Drive Buy Rating - TipRanks
MBX Bio stock initiated at Market Outperform by Citizens (MBX) - Seeking Alpha
MBX Biosciences director Pescovitz buys $45,311 in stock By Investing.com - Investing.com Canada
MBX Biosciences director Pescovitz buys $45,311 in stock - Investing.com
MBX Biosciences initiated with an Outperform at Citizens JMP - TipRanks
MBX Biosciences adds biotech veteran to board By Investing.com - Investing.com South Africa
MBX Biosciences adds biotech veteran to board - Investing.com Australia
MBX Biosciences Appoints Steve Hoerter to Board - TipRanks
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors - GlobeNewswire
From $2.4B Exit to Next Biotech Success: Pharma Veteran Steve Hoerter Strengthens MBX Board - Stock Titan
Charles Schwab Investment Management Inc. Invests $1.72 Million in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Bank of New York Mellon Corp Buys Shares of 23,914 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
MBX Biosciences Unveils Next-Gen Peptide Therapies: CEO Presentation at Major Healthcare Conference - Stock Titan
MBX Biosciences Inc Reports Q4 2024 Net Loss of $15.6 Million, S - GuruFocus
MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts - TipRanks
MBX Biosciences reports Q4 EPS (47c), consensus (59c) - MSN
MBX Biosciences stock jumps 5% on clinical trial progress By Investing.com - Investing.com Australia
MBX Biosciences stock jumps 5% on clinical trial progress - Investing.com India
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - marketscreener.com
MBX Biosciences Announces Enrollment Completion in Phase 2 Avail™ Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025 - Nasdaq
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide - Yahoo Finance
Rhumbline Advisers Purchases New Stake in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Rhumbline Advisers Purchases New Holdings in MBX Biosciences, Inc. (NYSE:MBX) - The AM Reporter
MBX Biosciences Announces Additions to Leadership Team - GlobeNewswire
MBX Biosciences strengthens leadership team with new SVPs By Investing.com - Investing.com Canada
MBX Biosciences Announces Additions To Leadership Team -March 05, 2025 at 08:53 am EST - Marketscreener.com
MBX Biosciences strengthens leadership team with new SVPs - Investing.com India
MBX Biosciences, Inc.’s Lock-Up Period Will Expire on March 12th (NYSE:MBX) - Defense World
MBX Biosciences Completes Enrollment In Phase 2 Avail Trial Of Canvuparatide For HP - Nasdaq
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - The Manila Times
MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109 - TipRanks
Can This Overenrolled Clinical Trial Transform Hypoparathyroidism Treatment? - StockTitan
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Acquires 47,502 Shares of Stock - MarketBeat
Insider Buying: MBX Biosciences, Inc. (NYSE:MBX) Director Purchases 143,170 Shares of Stock - MarketBeat
Major Stakeholders Double Down on MBX Biosciences with Substantial Stock Purchases! - TipRanks
Mbx biosciences director Carl Gordon purchases over $2 million in stock - Investing.com Nigeria
Mbx biosciences director Carl Gordon purchases over $2 million in stock By Investing.com - Investing.com South Africa
OrbiMed Advisors makes $2 million investment in MBX Biosciences By Investing.com - Investing.com Nigeria
MBX Biosciences to Participate in March Investor Conferences - GlobeNewswire
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):